Skip To Main Content
Berkeley Lovelace Jr. on Muck Rack

Berkeley Lovelace Jr.

Verified
Washington, D.C.
As seen in: NBC News, MSN, MSN Australia, MSN Canada, MSN New Zealand, MSN Singapore, MSN UK, Yahoo Life, USA Today, Yahoo News, Yahoo Singapore and
💊🏛️ @NBCNews Medical Reporter covering FDA, drug pricing and health care
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Berkeley

Contact Berkeley, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

She thought she had insurance coverage. Then a tumor was flagged as a pre-existing condition.

|
By Berkeley Lovelace Jr. Verified, Jessica Herzberg Verified, Anne Thompson Verified
| NBC News Verified
Aug. 27, 2026, 5:57 PM EDT This is part of The Cost of Denial, NBC News’s reporting on insurance in America. If you are dealing with seemingly inappropriate bills or a denial of coverage, care or repairs for health, home or auto, email us at Costofdenial@nbcuni.com.
Open in Who Shared View Duplicates (2) Issue with article?

Who’s tracking the risks from peptides? In many cases, no one

|
By Berkeley Lovelace Jr. Verified, Lily Alvino
| NBC News Verified
After Sarah Moran took a dose of a popular peptide in February, she said, her heart began racing when she stood up, and she experienced dizziness that lasted for days.
Open in Who Shared Issue with article?

FDA Approves ‘Game-Changing’ Pancreatic Cancer Drug

|
By Berkeley Lovelace Jr. Verified, Erika Edwards Verified
| TODAY Verified
The Food and Drug Administration on Wednesday approved a groundbreaking pancreatic cancer drug that experts predict will transform treatment for the notoriously deadly disease. The drug, Revolution Medicines’ Rasonque, or daraxonrasib, was approved for patients with advanced pancreatic cancer who have already tried a prior treatment, such as chemotherapy, the agency said.
Open in Who Shared Issue with article?
See all 10,859 licensed articles (10,863 Total)